WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
NeOnc Technologies received Investigational New Drug authorization from the Department of Health - Abu Dhabi for its lead candidate NEO212, targeting aggressive brain cancers. The company has completed its Phase 1 dose-escalation study and identified 610 mg as the recommended Phase 2 dose, with plans for a Type B meeting with the FDA.
Key figures
- Drug Name
- NEO212
- Phase 2 dose mg
- 610
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.